Article Figures & Data
Figures
- FIGURE 1.
Schematic outline of study. Within 35 d before tumor surgery or biopsy, MR imaging (mean, 15 d prior) and 18F-FET PET/CT (mean, 8 d) and 18F-DOPA PET/CT (mean, 6 d) were performed. Histopathology served as gold standard. Mean intervals to surgery are noted in time scale.
- FIGURE 2.
Display of transaxial contrast-enhanced T1-weighted MR imaging, 18F-FET, and 18F-DOPA PET/CT scans of patient with recurrent GBM and primary GBM. In both patients, 18F-FET uptake (SUVmax and SUVmean, 6.1 and 5.6, respectively) was higher than that of 18F-DOPA (SUVmax and SUVmean, 4.4 and 2.5, respectively).
- FIGURE 3.
Display of transaxial contrast-enhanced T1-weighted MR imaging, 18F-FET, and 18F-DOPA PET/CT scans of 2 patients with multifocal GBM. In both patients, 18F-FET and 18F-DOPA depicted all lesions.
- FIGURE 4.
Display of transaxial 18F-FET and 18F-DOPA PET/CT scans of patient with primary glioma affecting basal ganglia. Striatal uptake does not significantly compromise tumor delineation.
Tables
Patient no. Age (y) Sex Primary/recurrent HGG Histology Lesion site Previous therapy 1 47 M R Primary GBM Left temporal Surgery, radiochemotherapy 2 45 F R Secondary GBM Multifocal Surgery, radiochemotherapy 3 49 M R Primary GBM Left frontal Surgery, radiochemotherapy 4 50 M R Primary GBM Multifocal Surgery, radiochemotherapy 5 73 M R Primary GBM Left frontal Surgery, radiochemotherapy 6 42 M R Primary GBM Right parietooccipital Surgery, radiochemotherapy 7 43 M R Primary GBM Left parietal Surgery, radiochemotherapy 8 41 F R Anaplastic astrocytoma III Left temporal Surgery, radiochemotherapy 9 44 M R Anaplastic astrocytoma III Right temporal Surgery, radiochemotherapy 10 70 F R Primary GBM Left temporal Surgery, radiochemotherapy 11 51 F R Primary GBM Left parietal Surgery, radiochemotherapy 12 60 M R Primary GBM Left temporal Surgery, radiochemotherapy 13 67 M R Primary GBM Left frontal Surgery, radiochemotherapy 14 55 M R Primary GBM Left temporal Surgery, radiochemotherapy 15 54 F R Primary GBM Right cerebellar Surgery, radiochemotherapy 16 33 M R Oligoastrocytoma III Left frontal Surgery, radiotherapy 17 57 M R Primary GBM Right parietal Surgery, radiochemotherapy 18 58 M R Primary GBM Right temporooccipital Surgery, radiochemotherapy 19 61 M R Primary GBM Right parietal Surgery, radiochemotherapy 14/2 55 M R Primary GBM Left parietal Surgery, radiochemotherapy 17/2 55 M R Primary GBM Right parietal Surgery, radiochemotherapy 20 25 M R Secondary GBM Right temporal Surgery, radiotherapy 21 75 M R Primary GBM Right temporal Surgery, radiochemotherapy 10/2 71 F R Primary GBM Left temporal Surgery, radiochemotherapy 22 33 M R Primary GBM Right frontal Surgery, radiochemotherapy 23 77 F P Primary GBM Right frontal None 24 80 F P Primary GBM Left parietooccipital None 25 51 M P Primary GBM Right frontal None 26 65 F P Primary GBM Left temporal None 27 40 F P Pilocytic astrocytoma i Right basal ganglia None 10/2; 14/2; 17/2 = 3 patients were imaged twice.
Parameter 18F-FET SUVmean 18F-DOPA SUVmean 18F-FET SUVmax 18F-DOPA SUVmax 18F-FET TBR SUVmean 18F-DOPA TBR SUVmean 18F-FET TBR SUVmax 18F-DOPA TBR SUVmax All Mean 4.0 3.5 4.9 4.3 3.8 3.4 3.3 3.0 SD 2.0 1.6 2.3 2.0 1.7 1.2 1.6 1.1 Range 2.0–11.9 2.0–9.2 2.2–13.3 2.3–10.3 2.0–10.8 2.1–8.4 1.8–9.5 2.0–6.9 P <0.001 <0.001 0.004 0.086 Newly diagnosed HGG Mean 4.4 3.5 5.6 4.7 4.3 3.6 3.6 3.3 SD 1.4 1.7 2.0 2.7 1.4 1.2 1.3 1.3 Range 3.2–6.8 2.5–6.5 4.0–9.0 2.9–9.4 2.9–6.2 2.6–5.4 2.7–6.0 2.2–5.5 P 0.043 0.08 0.043 0.225 Recurrent HGG Mean 3.9 3.5 4.7 4.2 3.7 3.4 3.2 3.0 SD 2–1 1.7 2.4 1.8 1.8 1.2 1.6 1.0 Range 2.0–11.9 2.0–9.2 2.2–13.3 2.3–10.3 2.0–10.8 2.1–8.4 1.8–9.5 2.0–6.9 P 0.008 0.003 0.034 0.201 Respective SUVmax and SUVmean and tumor-to-background values for 18F-DOPA and 18F-FET for entire cohort and both subgroups (newly diagnosed and recurrent HGG).
